Ken Song

Title: Ken Song: Innovator in Radiopharmaceuticals

Introduction

Ken Song is a prominent inventor based in San Diego, CA, known for his contributions to the field of radiopharmaceuticals. With a total of 4 patents, he has made significant strides in developing innovative compositions that enhance cancer treatment.

Latest Patents

One of Ken Song's latest patents is focused on stabilized compositions of radionuclides and their uses. This patent outlines radiopharmaceutical compositions that include various stabilizing agents, an aqueous vehicle, and a conjugate comprising a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide, such as a monocyclic peptide, designed to bind with tumor targets. The stabilizing agents may include a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Additionally, the patent provides methods for preparing these radiopharmaceutical compositions and treating cancer through their administration.

Career Highlights

Ken Song is currently associated with Rayzebio, Inc., where he continues to innovate in the field of radiopharmaceuticals. His work focuses on creating effective treatments that leverage the unique properties of radionuclides to target cancer cells.

Collaborations

Throughout his career, Ken has collaborated with notable colleagues, including Daniel Daeik Kim and Gang Chen. These partnerships have contributed to the advancement of his research and the development of new therapeutic approaches.

Conclusion

Ken Song's work in radiopharmaceuticals exemplifies the impact of innovation in medical science. His patents and ongoing research are paving the way for more effective cancer treatments, showcasing the importance of collaboration and creativity in the field.